Literature DB >> 1819713

Platelet-activating factor in cardiovascular stress situations.

R Rabinovici1, T L Yue, G Feuerstein.   

Abstract

Since the elucidation of its chemical structure two decades ago, platelet-activating factor (PAF) has emerged as an important mediator of various cardiovascular stress situations. Most notably, PAF was implicated as a key factor in the septic shock syndrome, based on the similarities between endotoxin and PAF biological effects, the elevation of circulating and tissue levels of PAF during endotoxemia, and the protective effect of PAF antagonists in the septic state. In addition, accumulating data suggest the involvement of PAF in the pathophysiological processes associated with ischemia, hemorrhage and trauma, where PAF exerts its effects directly on cells and blood elements or indirectly through interactions with other mediators such as cytokines and prostaglandins. Nevertheless, the relative contribution of PAF to the pathophysiological processes in endotoxemia is still unknown and should await further investigations. The primary aims of this chapter are: to delineate the effects of PAF on the cardiovascular system, to summarize the data which suggest the involvement of PAF in stress situations of the cardiovascular system, and to identify areas where future experimental efforts should be focused.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1819713     DOI: 10.1007/BF02536543

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  99 in total

1.  Effects of ONO-6240, a platelet-activating factor antagonist, on endotoxin shock in unanesthetized sheep.

Authors:  T Toyofuku; K Kubo; T Kobayashi; S Kusama
Journal:  Prostaglandins       Date:  1986-02

Review 2.  Potential role of platelet-activating factor in renal pathophysiology.

Authors:  G Camussi
Journal:  Kidney Int       Date:  1986-02       Impact factor: 10.612

3.  Production and effects of platelet-activating factor in the rat brain.

Authors:  R Kumar; S A Harvey; M Kester; D J Hanahan; M S Olson
Journal:  Biochim Biophys Acta       Date:  1988-11-25

4.  Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives.

Authors:  B B Vargaftig; J Lefort; M Chignard; J Benveniste
Journal:  Eur J Pharmacol       Date:  1980-07-25       Impact factor: 4.432

5.  Effect of platelet-activating factor on coronary circulation of the domestic pig.

Authors:  G Feuerstein; L M Boyd; D Ezra; R E Goldstein
Journal:  Am J Physiol       Date:  1984-03

6.  Hemodynamic effects of platelet activating factor in the dog kidney in vivo.

Authors:  H Scherf; A S Nies; U Schwertschlag; M Hughes; J G Gerber
Journal:  Hypertension       Date:  1986-09       Impact factor: 10.190

7.  Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs.

Authors:  J L Kenzora; J E Pérez; S R Bergmann; L G Lange
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

8.  Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism.

Authors:  S A Cannistra; E Vellenga; P Groshek; A Rambaldi; J D Griffin
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

9.  Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor.

Authors:  R S Farr; M L Wardlow; C P Cox; K E Meng; D E Greene
Journal:  Fed Proc       Date:  1983-11

10.  The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations.

Authors:  J Benveniste; C Boullet; C Brink; C Labat
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.